cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25402/pgs.14778426
title: Supplementary table 1. The target value range of each mutant of the quality control. Supplementary table 2. The judging rule of the KRAS mutant gene. Supplementary table 3. Detection of the mutKRAS ctDNA in all enrolled patients.

description: Supplementary table 1. The target value range of each mutant of the quality controlSupplementary table 2. The judging rule of the KRAS mutant gene.Supplementary table 3. Detection of the mutKRAS ctDNA in all enrolled patients.<br>Background: The prognosis of resectable pancreatic cancer (PC) patients with the same stage of disease is highly variable. The purpose of this study is to establish a scoring system for preoperative screening of resectable patients. Methods: The clinical information and laboratory tests of 105 resectable patients with PC were enrolled and analysed. Results: The consistency of clinical stage and pathological stage was poor (κ = 0.193, P &lt; 0.003). We performed a comprehensive scoring system with KRAS mutations in circulating tumor DNA (mutKRAS ctDNA) for the resectable patients. Patients with higher scores were more prone to early postoperative recurrence and poorer prognosis. Conclusions: The scoring system can help preoperatively screen out resectable patients who are prone to early postoperative recurrence.<br>
DOI: 10.25402/pgs.14778426.v1
title: Supplementary table 1. The target value range of each mutant of the quality control. Supplementary table 2. The judging rule of the KRAS mutant gene. Supplementary table 3. Detection of the mutKRAS ctDNA in all enrolled patients.

description: Supplementary table 1. The target value range of each mutant of the quality controlSupplementary table 2. The judging rule of the KRAS mutant gene.Supplementary table 3. Detection of the mutKRAS ctDNA in all enrolled patients.<br>Background: The prognosis of resectable pancreatic cancer (PC) patients with the same stage of disease is highly variable. The purpose of this study is to establish a scoring system for preoperative screening of resectable patients. Methods: The clinical information and laboratory tests of 105 resectable patients with PC were enrolled and analysed. Results: The consistency of clinical stage and pathological stage was poor (κ = 0.193, P &lt; 0.003). We performed a comprehensive scoring system with KRAS mutations in circulating tumor DNA (mutKRAS ctDNA) for the resectable patients. Patients with higher scores were more prone to early postoperative recurrence and poorer prognosis. Conclusions: The scoring system can help preoperatively screen out resectable patients who are prone to early postoperative recurrence.<br>
DOI: 10.25402/pgs.17205983
title: Supplementary Table 2: Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.docx

description: <b>Supplementary
 Table 2.</b> Call rate for genotyped SNPs and number of cases, included into
 analyses of associations with total cholesterol and low-density lipoprotein
 cholesterol change, baseline carotid intima-media thickness, and its change
 during rosuvastatin therapy.
DOI: 10.25402/pgs.17205986
title: Supplementary Table 4: Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.docx

description: <b>Supplementary
 Table 4.</b> Associations of polymorphisms in genes involved in lipid
 metabolism and genes of membrane transporters with baseline total cholesterol
 level.
DOI: 10.25402/pgs.17205989
title: Supplementary Table 5: Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.docx

description: <b>Supplementary Table
5.</b> Post-hoc analysis of statistical power for the
associations of single nucleotide polymorphisms with total cholesterol,
low-density lipoprotein cholesterol, and carotid intima-media thickness change.
DOI: 10.25402/pgs.17205992
title: Supplementary Table 1: Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.docx

description: <b>Supplementary
 Table 1.</b> Call rate for genotyped SNPs and the number of available cases
 in the analyses of associations of genotype with baseline lipid levels and
 baseline carotid intima-media thickness.
DOI: 10.25402/pgs.17205995
title: Supplementary Table 3: Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.docx

description: <b>Supplementary
 Table 3.</b> Call rate for genotyped single nucleotide polymorphisms,
 included into genetic association analysis of coronary artery disease
 susceptibility.
DOI: 10.25402/pgs.17211908
title: Supplementary Tables: Association of NAT-2 gene polymorphisms towards lung cancer susceptibility and prognosis in North Indian patients treated with platinum-based chemotherapy.docx

description: Supplementary Tables
 S1–S8
DOI: 10.15468/dl.2nrakw
title: Occurrence Download

description: A dataset containing 17346 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Solanum angustifolium Houst. ex Mill.)"
 ]
}

 The dataset includes 17346 records from 412 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0019439-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.g7ddyy
title: Occurrence Download

description: A dataset containing 2396 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Hemigrapsus takanoi Asakura & Watanabe, 2005"
 ]
}

 The dataset includes 2396 records from 70 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0019440-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ss8vmx
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "StateProvince is New South Wales",
 "TaxonKey is Scleropages leichardti Günther, 1864"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0019441-240506114902167/datasets/export for details.
DOI: 10.25402/pgs.19076954
title: Supplementary materials: Pharmacogenomic Prescribing Opportunities in Percutaneous Coronary Intervention and Bone Marrow Transplant Patients.pdf

description: Supplementary Figure
 1. Flow diagram summarizing the number of patients with medication data
 available at each encounter across the two study populations.
 Supplemental Table 1.
 List of 65 medications collected in the PCI and allo-HCT populations with
 corresponding CPIC
 level of evidence and FDA evidence classification (sorted alphabetically).
 Supplementary Table
 2. Summary of CYP2C19 Simulation Analysis
 Supplementary Table
 3. Summary of CYP2D6 Simulation Analysis
 
 




Supplementary Table 4. Summary of Simulation
Analysis for additional genes
DOI: 10.25402/pgs.19076954.v1
title: Supplementary materials: Pharmacogenomic Prescribing Opportunities in Percutaneous Coronary Intervention and Bone Marrow Transplant Patients.pdf

description: Supplementary Figure
 1. Flow diagram summarizing the number of patients with medication data
 available at each encounter across the two study populations.
 Supplemental Table 1.
 List of 65 medications collected in the PCI and allo-HCT populations with
 corresponding CPIC
 level of evidence and FDA evidence classification (sorted alphabetically).
 Supplementary Table
 2. Summary of CYP2C19 Simulation Analysis
 Supplementary Table
 3. Summary of CYP2D6 Simulation Analysis
 
 




Supplementary Table 4. Summary of Simulation
Analysis for additional genes
DOI: 10.25402/pgs.19195805
title: Supplementary tables 1A & B: Pharmacogenetics research in Brazil: a systematic review

description: Table
 S1-A: Noticeable updates of this study when compared with Rodrigues-Soares et
 al. (2018) - doi: 10.1038/s41397-018-0015-7.
 
 
 




Table S1-B: Information considering all articles
included in this review.
DOI: 10.25402/pgs.19270943
title: Supplementary tables: CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study

description: Supplementary
 Table 1: CYP2D6 genotypes, variant positions, and average sequencing coverage
 in 96 Malagasy samples
 Supplementary
 Table 2: Novel variant positions not previously annotated in PharmVar in 23
 Malagasy samples
 Supplementary
 Table 3: Frequencies of novel variant positions not previously annotated in
 PharmVar in gnomAD populations
 
 




Supplementary Table 4: Complete SNP profiles of
three Malagasy subjects with novel exonic variants determined by NGS
DOI: 10.25402/pgs.19271144
title: Supplemtary table: Association of polymorphisms in ARRB2 (B-Arrestin2) and clinical response to methadone for pain in advanced cancer

description: Supplementary
 Table 1. Multiple regression analysis
 for patient characteristic variables for study population for methadone dose
 and pain score
DOI: 10.25402/pgs.19519765
title: Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews: supplementary data

description: Search
 strategy – Pubmed
 Table
 S1. General characteristics and strategies of the included systematic
 reviews.
 <b>Table S2.</b> Methodological
 quality of included systematic reviews, according to AMSTAR-2.
DOI: 10.25402/pgs.19619022
title: Premarket assessment of molecular alterations in drug targets: a case study of 2020 drug approvals: Supplementary data

description: Aim: Molecular alterations in drug targets may result in differential drug activity. Therefore, the authors
aimed to characterize how molecular alterations in drug targets were assessed during drug development.
Materials & methods: The authors analyzed nonclinical and clinical study reports submitted to the US FDA
for novel drugs approved in 2020 to determine if in vitro studies, animal models or clinical studies assessed
molecular alterations in the drug target. Results & conclusion: Assessment of the impact of molecular
alterations in drug targets on drug activity varies considerably depending on the type of assessment and
therapeutic area. Premarket assessment of drug target molecular alterations is common in the oncology
setting, less frequent in the genetic disease setting and rare for other diseases.
DOI: 10.25402/pgs.20065946
title: Genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants: supplemental material

description: Drug-induced long QT syndrome (diLQTS) is an adverse effect of many commonly prescribed drugs, and
it can increase the risk for lethal ventricular arrhythmias. Genetic variants in pharmacodynamic genes
have been associated with diLQTS, but the strength of the evidence for each of those variants has not yet
been evaluated. Therefore, the purpose of this review was to evaluate the strength of the evidence for
pharmacodynamic genetic variants associated with diLQTS using a novel, semiquantitative scoring system
modified from the approach used for congenital LQTS. KCNE1-D85N and KCNE2-T8A had definitive and
strong evidence for diLQTS, respectively. The high level of evidence for these variants supports current
consideration as risk factors for patients that will be prescribed a QT-prolonging drug.
DOI: 10.25402/pgs.20375490
title: Identification of RNA modification-associated single nucleotide polymorphisms in genomic loci for low-density lipoprotein cholesterol concentrations: Supplementary tables

description: Introduction: Genome-wide association studies have identified approximately 1000 lipid-associated loci,
but functional variants are less known. Materials & methods: The authors identified RNA modificationrelated
single nucleotide polymorphisms (RNAm-SNPs) in summary data from a genome-wide association
study. By applying Mendelian randomization analysis, the authors identified gene expression levels
involved in the regulation of RNAm-SNPs on low-density lipoprotein cholesterol (LDL-C) levels. Results:
The authors identified 391 RNAm-SNPs that were significantly associated with LDL-C levels. RNAm-SNPs
in NPC1L1, LDLR, APOB, MYLIP, LDLRAP1 and ABCA6 were identified. The RNAm-SNPs were associated
with gene expression. The expression levels of 112 genes were associated with LDL-C levels, and some of
them (e.g., APOB, SMARCA4 and SH2B3) were associated with coronary artery disease. Conclusion: This
study identified many RNAm-SNPs in LDL-C loci and elucidated the relationship among the SNPs, gene
expression and LDL-C.
DOI: 10.25402/pgs.20375490.v1
title: Identification of RNA modification-associated single nucleotide polymorphisms in genomic loci for low-density lipoprotein cholesterol concentrations: Supplementary tables

description: Introduction: Genome-wide association studies have identified approximately 1000 lipid-associated loci,
but functional variants are less known. Materials & methods: The authors identified RNA modificationrelated
single nucleotide polymorphisms (RNAm-SNPs) in summary data from a genome-wide association
study. By applying Mendelian randomization analysis, the authors identified gene expression levels
involved in the regulation of RNAm-SNPs on low-density lipoprotein cholesterol (LDL-C) levels. Results:
The authors identified 391 RNAm-SNPs that were significantly associated with LDL-C levels. RNAm-SNPs
in NPC1L1, LDLR, APOB, MYLIP, LDLRAP1 and ABCA6 were identified. The RNAm-SNPs were associated
with gene expression. The expression levels of 112 genes were associated with LDL-C levels, and some of
them (e.g., APOB, SMARCA4 and SH2B3) were associated with coronary artery disease. Conclusion: This
study identified many RNAm-SNPs in LDL-C loci and elucidated the relationship among the SNPs, gene
expression and LDL-C.
DOI: 10.25402/pgs.20418045
title: XDH genotypes through gene–gene interactions with NUDT15 affect azathioprine-induced leukopenia in Chinese patients: Supplementary materials

description: Aim: To investigate whether genotypes of XDH, GMPS and MOCOS were associated with azathioprineinduced
adverse drug reaction (ADR) and had the gene–gene interactions with NUDT15 rs116855232
to induce leukopenia. Methods: Patients who had taken azathioprine were recruited. Genotyping of
those gene was performed. Risk factor to ADR was analyzed by logistic regression. The generalized
multifactor dimensionality reduction (GMDR) was assessed based on gene–gene interactions with ADR.
Results: A total of 111 patients were included in this study, all of whom were Han Chinese. XDH rs2295475
was a risk factor of myelotoxicity (p = 0.022). NUDT15 rs116855232 was a risk factor of myelotoxicity,
grade ≥2 leukopenia and drug treatment termination (p-values were &lt;0.05). Rs2295475 and rs116855232
had a gene–gene interaction. The model was associated with grade ≥2 leukopenia (OR: 17.99; 95% CI:
4.11–78.81). Conclusion: Combined testing genotype for rs2295475 and rs116855232 could improve the
prediction of azathioprine-induced leukopenia.
DOI: 10.25402/pgs.20418045.v1
title: XDH genotypes through gene–gene interactions with NUDT15 affect azathioprine-induced leukopenia in Chinese patients: Supplementary materials

description: Aim: To investigate whether genotypes of XDH, GMPS and MOCOS were associated with azathioprineinduced
adverse drug reaction (ADR) and had the gene–gene interactions with NUDT15 rs116855232
to induce leukopenia. Methods: Patients who had taken azathioprine were recruited. Genotyping of
those gene was performed. Risk factor to ADR was analyzed by logistic regression. The generalized
multifactor dimensionality reduction (GMDR) was assessed based on gene–gene interactions with ADR.
Results: A total of 111 patients were included in this study, all of whom were Han Chinese. XDH rs2295475
was a risk factor of myelotoxicity (p = 0.022). NUDT15 rs116855232 was a risk factor of myelotoxicity,
grade ≥2 leukopenia and drug treatment termination (p-values were &lt;0.05). Rs2295475 and rs116855232
had a gene–gene interaction. The model was associated with grade ≥2 leukopenia (OR: 17.99; 95% CI:
4.11–78.81). Conclusion: Combined testing genotype for rs2295475 and rs116855232 could improve the
prediction of azathioprine-induced leukopenia.
DOI: 10.15468/dl.np26dg
title: Occurrence Download

description: A dataset containing 4898 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Solanum aviculare G.Forst.)"
 ]
}

 The dataset includes 4898 records from 128 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0019442-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25402/pgs.20488938
title: SLCO1B1 and ABCB1 variants synergistically influence the atorvastatin treatment response in south Indian coronary artery disease patients: supplementary files

description: Introduction: Atorvastatin exhibits wide interindividual variability in treatment response, limiting the
drug efficacy in coronary artery disease patients. Aim: To study the effect of genetic variants involved
in atorvastatin transport/metabolism and correlate their lipid-lowering efficacy. Materials & methods:
Genotyping was performed using 5?-hydrolysis probe method (n = 412), and the study evaluated the
treatment response in 86 patients. Results: Significant reduction in total cholesterol and low-density
lipoprotein cholesterol (LDL-C) were observed in SLCO1B1-rs4149056, rs4363657 and ABCB1-rs1045642
genotypes. The combined genotypes of ABCB1 and SLCO1B1 showed a strong synergistic effect in reducing
the total cholesterol and LDL-C. Diabetes and smoking were observed to influence the LDL-C reduction.
Conclusion: The genetic variants of SLCO1B1 and ABCB1 predict the lipid-lowering efficacy of atorvastatin,
and this may be useful in genotype-guided statin therapy for coronary artery disease patients.
DOI: 10.25402/pgs.20496204
title: ARG2 single-nucleotide polymorphism rs3742879 affects plasma arginase 2 levels, nitric oxide formation and antihypertensive therapy response in preeclampsia: supplementary files

description: Aim: This work examined whether ARG1 (rs2781659, rs2781667, rs2246012 and rs17599586) and ARG2
(rs3742879 and rs10483801) single-nucleotide polymorphisms (SNPs) are associated with antihypertensive
therapy responsiveness in preeclampsia (PE) and their effects on arginase isoforms and nitrite
concentrations in responsive and nonresponsive patients. Methods: SNP genotypes were determined by
TaqMan assays. Plasma arginase levels were measured by ELISA and nitrite concentrations were measured
using an ozone-based chemiluminescence assay. Results: The G allele for ARG2 rs3742879 (A&gt;G) was less
frequent in nonresponsive compared with responsive patients (15.5% vs 24.7%) and the G carriers of the
nonresponsive subgroup had lower arginase 2 (9.2 ± 7.5 ng/ml vs 19.1 ± 17.3 ng/ml) and higher nitrite
concentrations (110.2 ± 52.8 nM vs 78.5 ± 37.9 nM) than carriers of the AA genotype (all p &lt; 0.05).
Conclusion: ARG2 SNP rs3742879 is associated with diminished arginase 2 levels and increased nitric oxide
formation in nonresponsive PE patients.
DOI: 10.25402/pgs.20596824
title: Pharmacogenetic testing-guided treatment for oncology: an overview of reviews: Supplementary Data

description: Pharmacogenetics is the relationship between an individual’s genetic variations and their response
to pharmacological treatment. We conducted an overview of reviews on the use of post-treatment
pharmacogenetic testing for oncology, based on clinically relevant gene–drug pairs. We conducted a
search on Medline, Embase and Cochrane Library, from their inception to 18 June 2020. We selected
six eligible systematic reviews. The most studied drug categories were estrogen agonists/antagonists
and fluoropyrimidines associated with cytochrome P450 and dihydropyrimidine dehydrogenase genes
(CYP2D6 and DPYD), but many studies were classified as being of critically low or low quality. There
is a need for more high-quality primary studies and systematic reviews that assess the risk of bias,
with consistent definitions of clinical outcomes to consider the benefits of pharmacogenetic testing for
oncology.
DOI: 10.25402/pgs.20746726
title: Characterization of POR haplotype distribution in African populations and comparison with other global populations: Supplementary tables

description: Background & aim: POR is an enzyme that mediates electron transfer to enable the drug-metabolizing
activity of CYP450 proteins. However, POR has been understudied in pharmacogenomics despite this vital
role. The authors aimed to characterize the genetic variation in POR across African populations and
to compare the star allele (haplotype) distribution with that in other global populations. Materials &
methods: POR star alleles were called from whole-genome sequencing data using the StellarPGx pipeline.
Results: In addition to the common POR*1 and *28 haplotypes (defined by rs1057868), five novel rare
haplotypes were computationally inferred. No significant frequency differences were observed among
the majority of African populations. However, POR*28 was observed at a higher frequency in individuals
of non-African ancestry. Conclusion: This study highlights the distribution of POR alleles in Africa and
across global populations with a view toward informing future precision medicine implementation.
DOI: 10.15468/dl.3neen3
title: Occurrence Download

description: A dataset containing 94 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is BOLD:AAY5062"
 ]
}

 The dataset includes 94 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0019443-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25402/pgs.21036559
title: Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate: Supplementary data

description: Aim: A follow-up genome-wide association study (GWAS) in an extended cohort of rheumatoid arthritis
(RA) patients starting low-dose methotrexate (MTX) treatment was performed to identify further genetic
variants associated with alanine aminotransferase (ALT) elevation. Patients & methods: A GWAS was
performed on 346 RA patients. Two outcomes within the first 6 months of MTX treatment were assessed:
ALT &gt;1.5-times the upper level of normal (ULN) and maximum level of ALT. Results: SPATA9 (rs72783407)
was significantly associated with maximum level of ALT (p = 2.58 × 10-8) and PLCG2 (rs60427389) was
tentatively associated with ALT &gt;1.5 × ULN. Conclusion: Associations with SNPs in genes related to male
fertility (SPATA9) and inflammatory processes (PLCG2) were identified.
DOI: 10.25402/pgs.21269016
title: Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia - Supplementary Material

description:   
Supplementary Table S1. Treatment elements of consolidation therapy in CCLG-ALL-2018.
 Supplementary Table S2. Leucovorin rescue and MTX concentration
DOI: 10.25402/pgs.21269016.v1
title: Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia - Supplementary Material

description:   
Supplementary Table S1. Treatment elements of consolidation therapy in CCLG-ALL-2018.
 Supplementary Table S2. Leucovorin rescue and MTX concentration